Cargando…
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurof...
Autor principal: | Harder, Anja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052700/ https://www.ncbi.nlm.nih.gov/pubmed/33863389 http://dx.doi.org/10.1186/s40364-021-00281-0 |
Ejemplares similares
-
Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
por: Sweeney, Elizabeth E., et al.
Publicado: (2016) -
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020) -
Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022) -
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
por: Armstrong, Amy E., et al.
Publicado: (2023) -
ETS-targeted therapy: can it substitute for MEK inhibitors?
por: Tetsu, Osamu, et al.
Publicado: (2017)